Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bardin

Showing results (11-20 of 195) with videos related to

Pageof 20
Sort By:
Presse Medicale (Paris, France : 1983)|July 9, 2011
[Basic calcium phosphate crystal deposition disease]Thomas Bardin, Pascal Richette
Rheumatology (Oxford, England)|May 19, 2009
Can we make gout crystal clear? IntroductionThomas Bardin, Michael Doherty
BMC Medicine|July 4, 2017
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 3, 2019
The role of febuxostat in goutThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|November 3, 2009
Nephrogenic systemic fibrosisThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 15, 2014
Definition of hyperuricemia and gouty conditionsThomas Bardin, Pascal Richette
Annals of the Rheumatic Diseases|July 19, 2012
Purine-rich foods: an innocent bystander of gout attacks?Pascal Richette, Thomas Bardin
The Lancet. Rheumatology|January 30, 2024
Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout managementThomas Bardin, Pascal Richette
Joint Bone Spine|February 11, 2004
Structure-modifying agents for osteoarthritis: an updatePascal Richette, Thomas Bardin
Presse Medicale (Paris, France : 1983)|July 15, 2011
[The epidemiology and genetic of gout]Thomas Bardin, Pascal Richette
Pageof 20

Showing results (11-20 of 195) with videos related to

Sort By:
Pageof 20
Presse Medicale (Paris, France : 1983)|July 9, 2011
[Basic calcium phosphate crystal deposition disease]Thomas Bardin, Pascal Richette
Rheumatology (Oxford, England)|May 19, 2009
Can we make gout crystal clear? IntroductionThomas Bardin, Michael Doherty
BMC Medicine|July 4, 2017
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 3, 2019
The role of febuxostat in goutThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|November 3, 2009
Nephrogenic systemic fibrosisThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 15, 2014
Definition of hyperuricemia and gouty conditionsThomas Bardin, Pascal Richette
Annals of the Rheumatic Diseases|July 19, 2012
Purine-rich foods: an innocent bystander of gout attacks?Pascal Richette, Thomas Bardin
The Lancet. Rheumatology|January 30, 2024
Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout managementThomas Bardin, Pascal Richette
Joint Bone Spine|February 11, 2004
Structure-modifying agents for osteoarthritis: an updatePascal Richette, Thomas Bardin
Presse Medicale (Paris, France : 1983)|July 15, 2011
[The epidemiology and genetic of gout]Thomas Bardin, Pascal Richette
Pageof 20